Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The new plant will manufacture high-quality Type I borosilicate glass tubing
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
The new site enables end-to-end production of viral vector gene therapies
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Subscribe To Our Newsletter & Stay Updated